Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Girolamo Pelaia"'
Autor:
Girolamo Pelaia, Alessandro Vatrella, Corrado Pelaia, Angela Sciacqua, Luca Gallelli, Nicola Lombardo, Rocco Savino
Publikováno v:
Drug Design, Development and Therapy
Among the various members of the mitogen-activated protein kinase (MAPK) family, p38 MAPK subgroup is the most involved in airway and lung inflammation underlying asthma and chronic obstructive pulmonary disease (COPD). In particular, several environ
Autor:
Rocco Savino, Corrado Pelaia, Rosa Terracciano, Alessandro Vatrella, Maria Teresa Busceti, Girolamo Pelaia, Luca Gallelli
Publikováno v:
Drug Design, Development and Therapy
Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been recently approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines A
Autor:
Giuseppe Spaziano, Roberto Cannataro, Daniela Falcone, Luca Gallelli, Rosario Maselli, Rocco Savino, Mariarita Perri, Raffaele Serra, Girolamo Pelaia, Bruno D'Agostino
Publikováno v:
Drug Design, Development and Therapy
Theophylline is a natural compound present in tea. Because of its property to relax smooth muscle it is used in pharmacology for the treatment of airway diseases (ie, chronic obstructive pulmonary disease, asthma). However, this effect on smooth musc
Publikováno v:
Drug Design, Development and Therapy
Asthma is a widespread and heterogeneous inflammatory disease of the airways, which is characterized by several different phenotypes and endotypes. In particular, eosinophilic airway inflammation is a common pathologic trait of both allergic and nona